Pyruvate Dehydrogenase Kinase Inhibitor, AZD7545

Cell permeable: yes

Primary Target
pyruvate dehydrogenase kinases

Target IC₅₀: 36.8 & 6.4 nM for PDhK1 & PDhK2, respectively

Toxicity: Standard Handling (A)

A cell-permeable, bioavailable trifluomethylpropanamide compound that acts as a potent, selective, reversible, non-ATP-competitive inhibitor of pyruvate dehydrogenase kinases (IC₅₀ = 36.8 & 6.4 nM for PDhK1 & PDhK2, respectively). Inhibits PDhK3 at much higher concentrations (IC₅₀ = 600 nM) and robustly stimulates PDhK4 activity (>10 nM). Also shown to increase pyruvate dehydrogenase (PDh) activity in liver and muscle, and potentiates pyruvate oxidation (EC₅₀ = 105 nM in rat hepatocytes). Occupies lipoyl domain-binding site of PDhK2 (K_d = 19.2 nM) and disrupts the association of PDhK2 and inner lipoyl-bearing domain 2 of dihydrolipoyl acetyltransferase. Improves 24-h glucose profile and eliminates postparandial elevation in blood glucose in Zucker (fa/Fa) rats (10 mg/kg, b.i.d, p.o.,7 days).

Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.

Pyruvate Dehydrogenase Kinase Inhibitor, AZD7545, CAS 252017-04-2, is a potent, selective, reversible inhibitor of PDHK2 (IC₅₀ = 6.4 nM). Inhibits PDHK1 at higher levels (IC₅₀ = 36.8 nM).

Li, J., et al. 2009. J. Biol. Chem.284, 34458.
Tuganova, A., et al. 2007. Biochemistry46, 8592.
Morrell, J.A., et al. 2003. Biochem. Soc. Trans.31, 1168.
Mayers, R.M., et al. 2003. Biochem. Soc. Trans.31, 1165.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany